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miR-1269 promotes metastasis and forms a
positive feedback loop with TGF-b
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As patient survival drops precipitously from early-stage cancers to late-stage and metastatic
cancers, microRNAs that promote relapse and metastasis can serve as prognostic and
predictive markers as well as therapeutic targets for chemoprevention. Here we show that
miR-1269a promotes colorectal cancer (CRC) metastasis and forms a positive feedback
loop with TGF-b signalling. miR-1269a is upregulated in late-stage CRCs, and long-term
monitoring of 100 stage II CRC patients revealed that miR-1269a expression in their surgically
removed primary tumours is strongly associated with risk of CRC relapse and metastasis.
Consistent with clinical observations, miR-1269a significantly increases the ability of CRC
cells to invade and metastasize in vivo. TGF-b activates miR-1269 via Sox4, while miR-1269a
enhances TGF-b signalling by targeting Smad7 and HOXD10, hence forming a positive
feedback loop. Our findings suggest that miR-1269a is a potential marker to inform adjuvant
chemotherapy decisions for CRC patients and a potential therapeutic target to deter
metastasis.
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M
any solid tumours progress through stages while
accumulating genetic alterations and reprogramming
microenvironments1,2. Ranked among the most
common cancers and a leading cause of cancer-related
deaths3,4, colorectal cancer (CRC) progresses through an
adenomas to carcinoma sequence that eventually leads to
metastasis5,6. The stage of CRC is specified by the American
Joint Committee on Cancer (AJCC) tumour-node-metastasis
staging system, which provides the guideline for treatment. Stages
I and II are usually considered non-invasive, stage III has spread
to lymph nodes and stage IV involves metastasis. However,
although there is consensus to treat stage I CRC with only surgery
and stages III/IV CRC with chemotherapy in addition to surgery,
the overall benefit of adjuvant chemotherapy after resection
of stage II CRC remains unclear7. Still, chemotherapy likely
improves survival for certain subsets of stage II patients. As
patient survival drops from 80 to 90% for early-stage CRCs to
below 10% for late-stage and metastatic CRCs, it is important
to identify prognostic markers and therapeutic targets for
chemoprevention8.
microRNAs are small noncoding RNA molecules that suppress
gene expression via the 30 untranslated regions (UTRs) of target
mRNAs. Individual microRNA can control many target genes
and microRNA expression is often altered in cancer cells9.
Among them, microRNAs that promote relapse and metastasis
are of particular interest as potential prognostic biomarkers and
therapeutic targets10,11.
In this study, we show that miR-1269a expression is upregulated
in late-stage CRC and is associated with recurrence and metastasis
of disease-free stage II CRC patients. miR-1269a promotes CRC
cells to undergo epithelial–mesenchymal transition (EMT) and to
metastasize in vivo. Mechanistically, miR-1269 targets Smad7 and
HOXD10 to enhance transforming growth factor (TGF)-b
signalling, which in turn upregulates miR-1269 via Sox4.
Results
miR-1269 is upregulated in late-stage CRC tumours. To
investigate the roles of microRNAs in CRC progression, we
systematically compared microRNA expression levels in early-
versus late-stage CRC tumours using the latest COlon ADeno-
carcinoma (COAD) miRNASeq data set in The Cancer Genome
Atlas (TCGA)12 (see Methods). Differential expression analysis
based on read counts identified miR-1269 as a top microRNA
candidate that is upregulated in stage IV CRCs versus stage I and
II CRCs, with a P-value of 0.01 (Fig. 1a–c and Supplementary
Fig. 1, Supplementary Table 1). We did not include Stage III
CRCs in our TCGA analysis because their metastatic potential
was less clear and may vary widely between individuals.
The miR-1269 family has two isoforms, miR-1269a and
miR-1269b. To validate the TCGA analysis, we measured
miR-1269a and miR-1269b expression levels in 12 early-stage
and 17 late-stage CRC tumours acquired from the Weill
Cornell Medical College (WCMC) Colon Cancer Biobank
(Supplementary Table 2). Late-stage CRCs have higher miR-
1269a expression levels than early-stage CRCs in a statistically
significant manner according to reverse transcription–quanti-
tative PCR (RT–qPCR) measurements, consistent with the TCGA
finding (Fig. 1d). On the other hand, miR-1269b level was not
statistically different between early- and late-stage CRC samples.
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Figure 1 | miR-1269 level is associated with CRC progression, relapse and metastasis. (a) Volcano plot comparing miRNASeq data between Stage I/II
CRCs and Stage IV CRCs from the TCGA COAD data set. Each dot represents a microRNA. Dots in the upper right quadrant represent microRNAs that are
upregulated in Stage IV CRCs with enough statistical significance (P-valueo0.05 based on DESeq). (b) MA plot comparing miRNASeq data between Stage
I/II CRCs and Stage IV CRCs. Dots in the upper right quadrant represent microRNAs that are abundant and upregulated in Stage IV CRCs. (c) miR-1269
expression in early- (Stage I/II, n¼ 230) and late-stage (Stage IV, n¼ 59) CRCs. Each dot represents a CRC sample from COAD. (d) RT–qPCR
measurements of miR-1269a expression in early- (Stage I/II, n¼ 12) and late-stage (Stage III/IV, n¼ 17) CRC samples from WCMC Colon Cancer Biobank.
P-value was calculated based on Student’s t-test. (e) Kaplan–Meier analysis of relapses of Stage II CRC patients with high (red, n¼ 10) and low (blue,
n¼ 90) miR-1269a levels in their surgically removed primary tumours. (f) RT–qPCR measurements of miR-1269a expression in various CRC lines. Error
bars denote s.d. of triplicates.
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miR-1269 is a marker for CRC relapse and metastasis. Gen-
erally, it is difficult to predict whether stage II CRC patients will
relapse or develop metastasis after surgical removal of their
primary tumours, although 10–20% of stage II patients will
eventually relapse. To explore whether miR-1269a is a prognostic
marker for relapse and metastasis, we performed a clinical study
on 100 stage II CRC patients at the Catalan Institute of Oncology
(Tables 1 and 2)13. These disease-free patients were considered
‘low-risk’ for relapse and did not undergo chemotherapy after the
surgery. The patients were divided into two cohorts, ‘miR-
1269alow’ and ‘miR-1269ahigh’, based on the miR-1269a
expression levels measured in their surgically removed primary
tumours. Based on risk of relapse for stage II CRC, we allocated
the top 10% (10 patients) into the miR-1269ahigh cohort and the
rest (90 patients) into the miR-1269alow cohort to see whether
miR-1269a expression could distinguish the small subset of
patients who actually had high risk of relapse.
Follow-up revealed that high miR-1269a expression was
associated with relapse and metastasis of these disease-free
patients (logrank P¼ 0.002). The miR-1269ahigh cohort had a
significantly higher recurrence rate than the miR-1269alow cohort,
based on disease-free survival curves from Kaplan–Meier analysis
(Fig. 1e). Distant metastasis developed in only 18% of the patients
in the miR-1269alow cohort, but in 60% of the patients in the
miR-1269ahigh cohort (Table 1). The prognostic value of miR-
1269a for disease-free survival was significant (P¼ 0.015) in a
multivariable Cox’ proportional hazards model adjusted for age,
sex, subsite (left/right) and sub-stage (IIa/IIb; Table 2). These
results indicate that miR-1269a could be a potential marker
associated with a small subset of high-risk CRC Stage II patients
who were previously deemed low-risk and may benefit from
chemotherapy after surgery. We also explored cut points of miR-
1269a expression that stratified patients at 15 and 20 upper
percentiles, and the miR-1269ahigh cohort still had higher
recurrence rate than the miR-1269alow cohort in a statistically
significant way (P¼ 0.009 and 0.022). Similar analysis on miR-
1269b showed that miR-1269b was not associated with risk of
relapse (Supplementary Fig. 2a).
miR-1269a expression in CRC cell lines. We measured miR-
1269a expression in six commonly used CRC cell lines (Fig. 1f).
In general, miR-1269a levels are low in cells with relatively low
metastatic potential (HT29 and SW480), and are high in cells
with relatively high metastatic potential (DLD1, LoVo, LS174T
and SW620). One ambivalent case is the low miR-1269a
expression in HCT116 cells, which were derived from primary
adenocarcinoma but seem to possess metastatic potential. It is
likely that HCT116 cells have accumulated other metastasis-
promoting mutations. Notably, the miR-1269a level is sixfold
higher in SW620 cells than in SW480 cells. Originally from the
same CRC patient, SW480 was derived from a primary colon
adenocarcinoma before relapse, whereas SW620 was derived from
mesenteric lymph nodes metastases post-relapse14. Hence, this
controlled comparison between the two patient-matched cell lines
supported that miR-1269a levels are associated with metastatic
potential. Unlike miR-1269a, miR-1269b exhibited similar
expression levels in SW480 and SW620 cells (Supplementary
Fig. 2b). Therefore, we decided to focus on miR-1269a for the rest
of the study.
miR-1269a promotes CRC metastasis. To evaluate the effect of
miR-1269a on SW480 cells, which have low endogenous miR-
1269a expression, we ectopically expressed miR-1269a in SW480
cells. Ectopic miR-1269a only slightly increased cell growth
in vitro (Supplementary Fig. 3) and subcutaneous xenograft
tumour growth in vivo (Fig. 2a). However, Transwell migration
assay (Fig. 2b) and Matrigel invasion assay (Fig. 2c) showed that
ectopic expression of miR-1269a increased migration and inva-
sion of SW480 cells significantly.
To investigate whether miR-1269a promotes metastasis in vivo,
we used an established CRC orthotopic model by implanting
human CRC cells into cecum terminus of NOD/SCID mice15,16.
SW480 cells were infected with lentiviral vectors to establish two
stable lines that either expressed miR-1269a (SW480-miR-1269a)
Table 1 | Relationship between miR-1269a and
clinicopathological features of 100 stage II CRC patients.
miR-1269a expression
Variable Low (N¼90),
N (%)
High (N¼ 10),
N (%)
P value*
Median age, years 70.3 73.3
Age category, years
¼o70 38 (42.2) 3 (30) 0.26
470 52 (57.8) 7 (70)
Sex
Male 63 (70.0) 9 (90) 0.22
Female 27 (30.0) 1 (10)
Site
Left 53 (58.9) 8 (80) 0.31
Right 37 (41.1) 2 (20)
Stage
IIa 84 (93.3) 8 (80) 0.18
IIb 6 (6.7) 2 (20)
Distant metastasisw
Liver 7 (7.7) 4 (40) 0.24
Lung 3 (3.3) 0
Liverþ lung 1 (1.1) 0
Liverþ bone 0 1 (10)
CRC, colorectal cancer.
*A w2 test was applied to access the associations between miR-1269 expression and the
clinicopathological parameters.
wMetastasis occurred after surgery.
Table 2 | Multivariate analysis of miR-1269a prognosis.
Factor N (%) HR* 95% CI P value
miR-1269a
Low 90 (90) 1.00
High 10 (10) 3.95 (1.27–10.1) 0.016
Age (years)
470 59 (59) 1.00
¼o70 41 (41) 0.82 (0.34–1.95) 0.65
Sex
Female 28 (28) 1.00
Male 72 (72) 0.92 ( 0.44–3.45 ) 0.69
Site
Left 39 (39) 1.00
Right 61 (61) 1.23 (0.36–2.36) 0.86
Stage
IIa 92 (92) 1.00
IIb 8 (8) 1.24 (0.33–4.61) 0.75
CI, confidence interval; HR, hazard ratio.
P value was calculated using likelihood ratio test.
*Hazard ratio derived from a Cox proportional hazards model adjusted for age, sex, site and
stage.
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Figure 2 | miR-1269a promotes CRC metastasis. (a) Growth of subcutanous xenograft CRC tumour, as shown by tumour weight (upper panel) and
representative tumour images (lower panel), with a control vector (NC) or with ectopic miR-1269a expression (miR-1269a). Error bars denote s.d. of five
mice in each group. Scale bar, 5 mm. (b,c) Transwell assay measuring CRC cell migration (b) and invasion (c) with a control vector (NC) or with ectopic
miR-1269a expression (miR-1269a). Error bars denote s.d. of triplicates. Scale bar, 50mm. (d–f) Analysis of CRC liver metastasis in mice with orthotopic
(cecal) injection of SW480-NC and SW480-miR-1269a cells carrying luciferase and mCherry reporter constructs. Representative IVIS luciferase in vivo
images (d), bright field and fluorescent (mCherry) images of livers isolated from mice (e) and number of liver metastatic nodules (f) show ectopic miR-
1269a expression-promoted liver metastasis of SW480 cells. Scale bar, 8mm. (g–i) Analysis of CRC liver metastasis in mice with orthotopic (cecal)
injection of SW620-Anti-NC and SW620-Anti-miR-1269a cells carrying luciferase and mCherry reporter constructs. Representative IVIS luciferase in vivo
images (g), bright field and fluorescent (mCherry) images of livers (h) and number of liver metastatic nodules (i) show knockdown of endogenous miR-
1269a by antisense RNA suppressed liver metastasis of SW620 cells. Error bars denote s.d. of eight mice in each group. Scale bar, 8 mm. (j,k) H&E staining
of liver sections isolated from mice orthotopically injected with SW480-NC or SW480-miR-1269a cells (j) or SW6200-Anti-NC or SW620-Anti-miR-
1269a cells (k). Error bars denote s.d. of eight mice in each group. Scale bar, 15 mm. **Po0.01; ***Po0.001. Student’s t-test.
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or contained a control vector (SW480-NC). These cells also
carry constitutive luciferase and mCherry reporter constructs.
After cecal implantation of equal numbers of cells from both
lines, metastasis was tracked using the whole-body IVIS
bioluminescence imaging system. Once a mouse became
moribund, all mice were killed simultaneously and hepatic
metastases expressing mCherry were analysed by imaging the
entire liver with a fluorescent microscope. SW480-NC cells failed
to metastasize to liver in all 8 mice (0/8). In contrast, 7 out 8 (7/8)
mice injected with SW480-miR-1269a cells developed hepatic
metastases (Fig. 2d,e,f,j and Supplementary Fig. 4a,b). Hence,
ectopic miR-1269a expression promotes metastasis of SW480
cells in vivo.
To investigate whether silencing of miR-1269a expression in
metastatic cells impedes their ability to metastasize, we knocked
down endogenous miR-1269a levels in SW620 cells, the
metastatic counterpart of SW480 from the same patient. SW620
cells were infected with lentiviral vectors to establish two stable
lines that either expressed antisense RNA against miR-1269a
(SW620-Anti-miR-1269a) or contained a control vector (SW620-
Anti-NC). The mir-1269a knockdown efficiency in SW620-Anti-
miR-1269a cells was evaluated by a luciferase reporter
(Supplementary Fig. 5). Equal numbers of SW620-Anti-NC and
SW620-Anti-miR-1269a cells were implanted into the ceca of
NOD/SCID mice. All mice were simultaneously killed for
metastasis examination when one became moribund. Six out of
eight (6/8) mice injected with SW620-Anti-NC cells developed
hepatic metastases, whereas only 1 out of 8 (1/8) mice injected
with SW620-Anti-miR-1269a cells developed hepatic metastasis
(Fig. 2g,h,i,k and Supplementary Fig. 4c,d). Thus, miR-1269a
knockdown suppressed metastasis of SW620 cells in vivo.
In addition to the cecum-injection model, we performed
intravenous injection through tail vein with the same cells. In the
group injected with SW480-miR-1269 cells, all 10 mice developed
lung metastasis, with a large number of metastatic nodules
covering the entire lung. In contrast, only 4 out of 10 mice
injected with SW480-NC cells developed lung metastasis, with a
small number of metastatic nodules (Supplementary Fig. 6a–c).
miR-1269a also promoted CRC colonization of the liver. Only 1
out of the 10 mice injected with SW480-NC cells developed liver
metastasis, whereas 5 out of the 10 mice injected SW480-miR-
1269a cells developed liver metastasis (Supplementary Fig. 6d-f).
Consistent with SW480 cells, ectopic miR-1269a expression in
HCT116 also enhanced lung and liver metastasis, compared with
the control vector (Supplementary Fig. 6g,h). Therefore, miR-
1269a expression promoted colonization of circulating SW480
and HCT116 cells in the lung and the liver.
Similarly, equal numbers of SW620-Anti-NC and SW620-Anti-
miR-1269a were intravenously injected through tail vein. In the
control group (SW620-Anti-NC), all 10 mice (10/10) developed
lung metastasis and 4 out of 10 (4/10) developed liver metastasis,
which is consistent with the high metastatic potential of SW620.
miR-1269a knockdown significantly reduced lung and liver meta-
stasis of SW620 cells. In the SW620-Anti-miR-1269a group, only 3
out 10 (3/10) mice developed lung metastasis and 1 out 10 (1/10)
developed liver metastasis (Supplementary Fig. 6a–f). The SW620
data were further corroborated by knocking down miR-1269a in
LS174T cells, which also have high endogenous miR-1269a
expression. Injected LS174T control cells formed extensive meta-
stasis in the lung, lymph nodes in the lateral thoracic region and
the bone. In contrast, miR-1269a knockdown in LS174T cells
significantly reduced metastasis in these regions (Supplementary
Fig. 6i). Therefore, silencing of endogenous miR-1269a mitigated
colonization of circulating SW620 and LS174T cells.
Collectively, the in vitro migration and invasion assays and
in vivo metastasis assays, with ectopic expression of miR-1269a in
SW480 and HCT116 cells and knockdown of endogenous miR-
1269a in SW620 and LS174T cells, indicate that miR-1269a
promotes CRC metastasis.
miR-1269a promotes an EMT-like process. As an EMT-like
process has been associated with colon cancer metastasis17, we
examined whether miR-1269a promotes EMT. We measured the
levels of the epithelial marker E-cadherin and the mesenchymal
markers N-cadherin and Vimentin in SW480-miR-1269a and
SW480-NC cells using both western blot analysis and
immunofluorescence. Compared with the control SW480-NC
cells, which had high E-cadherin expression and low N-cadherin
and Vimentin expression, SW480-miR-1269a cells had
significantly downregulated E-cadherin expression and
upregulated N-cadherin and Vimentin expression (Fig. 3a,b).
Consistent with the EMT markers, SW480-miR-1269a cells
adopted a spindle-shaped, mesenchymal-like morphology in
contrast to the epithelial-like morphology of SW480-NC cells
(Fig. 3c). Hence ectopic miR-1269a expression causes SW480 cells
to undergo EMT.
We then examined whether silencing of miR-1269a could
impede the ability of cells to undergo EMT. As the metastatic
counterpart of SW480, SW620 cells have higher endogenous
miR-1269a expression levels than SW480 cells. miR-1269a
knockdown reduced N-cadherin and Vimentin levels in SW620
cells, as shown by immunofluorescence and western blot
(Fig. 3d,e). TGF-b1 treatment turned on N-cadherin and
Vimentin expression and turned down E-cadherin expression in
the control (SW620-Anti-NC) cells, which started to display a
mesenchymal-like morphology (Fig. 3f). In contrast, the effect of
TGF-b1 induction was much attenuated by miR-1269a knock-
down, as SW620-Anti-miR-1269a cells largely maintained
E-cadherin expression and the epithelial-like morphology in the
presence of TGF-b1 (Fig. 3d–f). Therefore, miR-1269a knock-
down impedes the ability of SW620 cells to undergo an EMT-like
process upon TGF-b induction. Together, the data indicate that
miR-1269a not only promotes an EMT-like process, but is also
involved with TGF-b-induced transformation of CRC cells.
TGF-b activates miR-1269a via Sox4. To explore the crosstalk
between miR-1269a and TGF-b, we treated SW480 cells with
TGF-b1 and measured the response of miR-1269a by RT–qPCR.
TGF-b1 treatment upregulated miR-1269a expression, suggesting
that TGF-b is an upstream regulator of miR-1269a (Fig. 4a).
Genomic analysis identified two Sox4-binding motifs at  173 to
 166 (site 1) and  947 to  940 (site 2) inside the putative
miR-169 promoter region (Fig. 4b). Notably, Sox4 is a down-
stream target gene of TGF-b18 and has been reported to be a
master regulator of EMT and cancer metastasis19. Therefore,
Sox4 is a potential intermediate between TGF-b and miR-1269a.
Notably, Sox4 expression level was higher in SW620 cells than in
SW480 cells, similar to miR-1269 (Supplementary Fig. 7).
We then tested whether Sox4 can activate the miR-1269a
promoter as suggested by their binding motifs. In SW480 cells,
ectopic expression of Sox4 caused a fourfold increase of
miR-1269a expression level, compared with cells transfected with
a control vector (Fig. 4c). We then tested whether Sox4 is the
intermediate regulator that is required for TGF-b-induced
miR-1269a upregulation. Compared with the control cells, Sox4
knockdown by short hairpin RNA (shSox4) completely abolished
the effect of TGF-b1 on miR-1269a expression, consistent
with Sox4 as an intermediate regulator between TGF-b1 and
miR-1269a (Fig. 4d).
To address whether Sox4 directly activates miR-1269a expres-
sion, we performed chromatin immunoprecipitation (ChIP)
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assays in SW480 and HT29 cells. ChIP confirmed that Sox4
proteins were recruited to both binding sites in the putative miR-
1269a promoter, with the majority of Sox4 bound to site 1
(Fig. 4e, f). To test whether the binding of Sox4 is sufficient to
activate miR-1269a expression, we cloned the putative miR-1269a
promoter sequence into a pGL4-basic vector, which were
subsequently transfected into SW480 and HT29 cells. A dual-
luciferase reporter assay revealed that ectopic expression of Sox4
activated the transcription of firefly luciferase that was driven by
the wild-type miR-1269a promoter. When the binding sequence
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Figure 3 | miR-1269a regulates EMT. (a–c) Western blot (a), immunofluorescence (b) and phase-contract images (c) of SW480 cells with a control
vector (NC) or with ectopic miR-1269a expression (miR-1269a). Ectopic miR-1269a downregulated the epithelial marker E-cadherin, upregulated the
mesenchymal markers N-cadherin and Vimentin, and changed cell morphology. (d–f) Immunofluorescence (d), western blot (e) and phase-contract
images (f) of SW620 cells with a control vector (Anti-NC) or with antisense RNA against endogenous miR-1269a (Anti-miR-1269a). SW620 cells are
either untreated (d, upper panel) or treated with TGF-b1 (d, lower panel). miR-1269a knockdown suppressed TGF-b1 induction of EMT, as indicated by
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morphology. Scale bar, 15mm.
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of site 1 was mutated, firefly luciferase expression dropped 6.8-
fold in SW480 cells and 5.4-fold in HT29. When the binding
sequence of site 2 was mutated, firefly luciferase expression
dropped 4.6-fold in SW480 and 5.7-fold in HT29 (Fig. 4g, h).
Therefore, Sox4 directly binds to these two sites to activate miR-
1269a expression.
We then examined whether endogenous Sox4 binding
to the miR-1269 promoter increases upon TGF-b induction.
We treated SW480 cells with TGF-b1 and then performed
ChIP. As expected, more Sox4 proteins were recruited to both
binding sites in the miR-1269 promoter after TGF-b1 treatment
(Fig. 4i). Next, to investigate whether Sox4 promotes in vivo
metastasis as miR-1269 does, we ectopically expressed
Sox4 in SW480 cells and implanted them into mouse ceca.
Consistent with ectopic miR-1269 expression, ectopic Sox4
expression significantly enhanced SW480 hepatic metastasis
(Fig. 4j,k).
Taken together, our data indicate that TGF-b upregulates miR-
1269a through Sox4, which binds to the two Sox4-binding sites in
the miR-1269a promoter to activate miR-1269a expression. Thus,
TGF-b, Sox4 and miR-1269a act synergistically to promote EMT
and metastasis.
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miR-1269a targets Smad7 and HOXD10. To determine
miR-1269a target genes, we searched for computationally pre-
dicted candidates using miRecords, which compiles 11 micro-
RNA targets prediction databases such as PicTar, miRanda,
TargetScan and RNA hybrid (Supplementary Table 3). We then
used RT–qPCR to compare expression levels of the candidate
genes between ectopic miR-1269a expression and control in
SW480 and HT29 cells. Among the candidates, homeobox
D10 (HOXD10) has been reported to suppress tumour invasion
and metastasis20, whereas Smad7 is a well-known antagonist
of TGF-b signalling21. Smad7 and HOXD10 were downregulated
in both SW480 and HT29 cells by miR-1269a (Fig. 5a,b).
Western blot confirmed that miR-1269a suppresses Smad 7 and
HOXD10 protein levels (Fig. 5c,d).
To test whether they are direct targets of miR-1269a,
the 30UTRs of the two genes were cloned downstream of
firefly luciferase. The luciferase reporters were then co-transfected
with a miR-1269a-expressing construct or an empty control
vector into SW480 cells. Cells with ectopic miR-1269a
expression had suppressed Smad7 and HOXD10 levels, in
contrast to the control cells, whereas mutation in the putative
miR-1269a seed regions in the 30UTRs of either Smad7 or
HOXD10 abrogated the suppression of miR-1269a (Fig. 5e
and Supplementary Fig. 8). Therefore, miR-1269a directly
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targets Smad7 and HOXD10 through the identified binding sites
in their 30UTR.
HOXD10 has been reported to suppress tumour invasion and
metastasis20. To test whether miR-1269a suppression of HOXD10
promotes invasion and metastasis, we transfected SW480 cells
with vector constructs expressing both miR-1269a and HOXD10
mRNA without its 30UTR (hence resistant to miR-1269a
suppression). Transwell migration and Matrigel invasion assays
revealed that ectopic expression of HOXD10 was able to abrogate
miR-1269a-induced cell migration and invasion (Fig. 5f). We
then ectopically expressed HOXD10 in SW620 cells and
implanted the cells orthotopically into mouse cecum termini.
Consistent with the in vitro migration and invasion assays,
ectopic HOXD10 expression dramatically reduced hepatic
metastasis in vivo (Fig. 5g,h).
miR-1269a and TGF-b forms a positive feedback loop. Smad7 is
a well-known antagonist of TGF-b signalling21, although the
effect of HOXD10 on TGF-b signalling is unclear. This raised the
question as to whether miR-1269a regulates TGF-b signalling in
CRC cells through its direct targets. Western blot showed that
ectopic expression of miR-1269 in SW480 cells enhanced Smad2
phosphorylation. Consistently, Knockdown of miR-1269 target
Smad7 or HOXD10 also promoted Smad2 phosphorylation
(Fig. 6a). To evaluate the effect of HOXD10 and Smad7 on
TGF-b targets gene expression, we established cell lines either
expressing Smad7 or HOXD10, or containing a control vector.
The cell lines were treated with TGF-b1 for 96 h before RT–qPCR
and western blot were performed to measure TGF-b target genes,
Slug, Snail and Sox4. As expected, TGF-b1 upregulated Slug, Snail
and Sox4 expression in cell lines with the control vector.
However, the upregulation was significantly reduced by ectopic
expression of Smad7 or HOXD10 (Fig. 6b–e and Supplementary
Fig. 9a–d), suggesting that HOXD10 is also an antagonist of
TGF-b signalling in CRC cells. Ectopic expression of Smad7 or
HOXD10 also reduced TGF-b induced miR-1269a upregulation,
consistent with the fact that Sox4 levels are down (Fig. 6f and
Supplementary Fig. 9e). Taken together, these data indicate that
Smad7 and HOXD10 are antagonists of TGF-b signalling.
As miR-1269a directly targets Smad7 and HOXD10, both of
which are antagonists of TGF-b signalling, we examined whether
miR-1269a upregulates TGF-b signalling. As showed in Fig. 6g–i
and Supplementary Fig. 9f–h, ectopic expression of miR-1269a
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increased the expression levels of all three target genes of TGF-b
signalling, Slug, Snail and Sox4, in SW480 and HT29 cells. Slug,
Snail and Sox4 are master regulators of EMT, and their
expression in SW480 cells downregulated E-cadherin and
upregulated N-cadherin (Fig. 6j). These data provide an
explanation for the strong induction of EMT by miR-1269a in
CRC cells—miR-1269a upregulates TGF-b signalling and its
target genes, Slug, Snail and Sox4, via suppression of
TGF-b antagonists Smad7 and HOXD10. To examine whether
miR-1269a induces TGF-b expression, we performed RT–qPCR
in SW480 cells that ectopically express miR-1269a. miR-1269a
increased TGF-b1 expression, but had little effect on TGF-b2 and
TGF-b3 expression (Supplementary Fig. 10). ELISA confirmed
that miR-1269a also increased TGF-b1 protein level in SW480
medium (Fig. 6k). miR-1269a seems to upregulate TGF-b1 via a
regulatory route independent of Smad7 and HOXD10, as
knockdown of Smad7 and HOXD10 did not affect TGF-b1 level
(Fig. 6i). Our studies suggest that TGF-b and miR-1269a form a
positive feedback loop, wherein TGF-b upregulates miR-1269
via Sox4, whereas miR-1269 upregulates TGF-b1 and enhances
TGF-b signalling by suppressing its antagonists Smad7 and
HOXD10 (Fig. 7).
Discussion
In this study, we performed differential analysis between early-
and late-stage CRCs in TCGA to identify miR-1269 as a top
candidate, which was confirmed by additional 29 CRC samples. A
study of 100 stage II CRC patients revealed that miR-1269a
expression level was associated with risk of relapse and metastasis.
Mechanistically, this is because miR-1269a and TGF-b form a
positive feedback loop via Sox4, HOXD10 and Smad7 to promote
EMT and metastasis.
miR-1269a was a somewhat surprising candidate that emerged
from our differential analysis because very little was known about
this microRNA. A global study of eight paired samples of normal
mucosa and CRC tumour reported that miR-1269 was one of the
16 microRNAs that were deregulated in tumour tissues22.
Nevertheless, a differential expression analysis between normal
and tumour tissues in TCGA did not suggest a statistically
significant change in miR-1269a expression. Regardless, our
analysis suggests that miR-1269a likely plays a more prominent
role in CRC relapse and metastasis than in oncogenesis. Hence,
the practice of grouping CRC tumours of various stages into a
single group may mask the complexity of microRNA regulation
during tumour progression.
miR-1269a does not promote metastasis alone; instead, it forms
a positive feedback loop with TGF-b. This finding is consistent
with the increasing appreciation that microRNAs form regulatory
motifs with protein regulators to confer robustness to biological
processes, and their subversion can expose cells to elevated
risk of malfunction23. Therefore, the context is important for
understanding the role of microRNAs in regulatory networks. For
example, positive feedback is known to amplify a response and
commits into a self-sustained mode that is autonomous to the
original stimuli. It is tempting to speculate that, once induced by
TGF-b, the miR-1269a-mediated feedback loop allows CRC cells
to become more autonomous. This would enhance the ability of
CRC cells to invade and metastasize to new microenvironments,
which would explain the strong pro-metastasis phenotype we
have observed.
Elevated TGF-b production is associated with high risk of CRC
relapse and metastasis24. Stromal cells in the CRC micro-
environment can also produce TGF-b, which increases the
efficiency of organ colonization by CRC cells. In a likely scenario,
TGF-b released from the microenvironment reaches a certain
concentration to activate the positive feedback loop in CRC cells
and promote their dissemination. Hence, miR-1269a may play an
integrated role in the TGF-b-mediated crosstalk between CRC
and stromal cells to confer a survival advantage to metastatic
cells.
On the other hand, we certainly have to caution against over-
simplification of CRC metastasis, which is a complicated process
involving many players. In fact, our analysis indicates that, unlike
miR-1269a, the association between TGF-b and relapse is not
statistically significant among the 100 disease-free stage II CRC
patients. This suggests that miR-1269a’s ability to promote
recurrence and metastasis does not completely depend on its
upregulation of TGF-b in tumour cells. Mutations could interfere
with this feedback loop, whereas miR-1269a might also affect
metastasis through other targets independent of TGF-b. Neither
miR-1269a nor the positive feedback loop is likely to be sufficient
or necessary for metastasis.
Methods
Cell lines. Human CRC cell lines SW480, SW620, HCT116, HT29, DLD1,
LoVo and LS174T were acquired from American Type Culture Collection and
cultured under the conditions recommended by the provider. For TGF-b
activation, the cells were treated with 10 ng ml 1 TGF-b1 for 96 h, and TGF-b1
was replaced after 48 h.
Kaplan–Meier relapse analysis and clinical specimens. The studies followed
informed consent and approval of the Ethical Committees at the Catalan
Institute of Oncology and Weill Cornell Medical College. Tumour relapse was
analysed by tracking 100 stage II CRC patients. The patients were divided into
two groups, ‘miR-1269low’ and ‘miR-1269high’, based on the miR-1269 expression
levels measured in their surgically removed primary tumours. microRNA
expression was measured using Solid IV small-RNA sequencing and bowtie2
mapped to miRbase 20. Sample counts were normalized according to the library
size using the DESeq bioconductor package (http://genomebiology.com/2010/11/
10/r106). The cutoff threshold was set to separate the top 10% miR-1269high
patients from the 90% ‘miR-1269low patients. The disease-free survival curves
were estimated using the Kaplan–Meier method and compared with the
log-rank test.
To evaluate miR-1269a expression in early- and late-stage CRC tumours, frozen
CRC specimens were acquired from the WCMC Colon Cancer Biobank. Total
RNA was then isolated from the frozen tissues using the Allprep DNA/RNA kit
(Qiagen).
Quantitative real-time RT–PCR analysis. Total RNA was extracted from the cells
using the TRIzol Reagent (Invitrogen). cDNA was synthesized from 500 ng of total
RNA in 20 ml of reaction volume using the High Capacity cDNA Archive Kit
TGF-β1
Smad7
HOXD10miR-1269a
Sox4
EMT, metastasis
Figure 7 | A positive feedback loop between TGF-b and miR-1269a. A
schematic illustration of the positive feedback loop. miR1269a upregulates
TGF-b1 and TGF-b signalling by suppressing its antagonists Smad7 and
HOXD10. TGF-b in turn upregulates miR-1269 through Sox4.
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(Applied Biosystems). miR-1269a and miR-1269b levels were measured by quan-
titative PCR using the TaqMan MicroRNA Assay (Applied Biosystems). Gene
expression levels were measured by quantitative PCR using the SYBR Green Sys-
tem (Applied Biosystems). All samples were run in triplicates and were repeated
three times. The respective miR-1269a and miR-1269b primers and U6 primer
were purchased from Applied Biosystems. Other primer sequences include:
HOXD10, 50-GTGCAGGAGAAGGAAAGCAAAG-30 and 50-TAACGCTCTTACT
GATCTCTAGGC-30 ; Smad7, 5’-TGCTCCCATCCTGTGTGTTAAG-3’ and 50-TC
AGCCTAGGATGGTACCTTGG-30 ; Slug, 50-CATGCCTGTCATACCACAAC-30
and 50-GGTGTCAGATGGAGGAGGG-30 ; Snail, 50-GAGGCGGTGGCAGAC
TAG-30 and 50-GACACATCGGTCAGACCAG-30 ; Sox4, 50-CACATCAAGCGA
CCCATGAAC-30 and 50-CCGGTACTTGTAGTCGGGGTAGT-30 ; TGF-b1,
50-CTCTCCGACCTGCCACAGA-30 and 50-AACCTAGATGGGCGCGATCT-30 ;
TGF-b2, 50-CCGCCCACTTTCTACAGACCC-30 and 50-GCGCTGGGTGGGAG
ATGTTAA-30; TGF-b3, 50-CTGGCCCTGCTGAACTTTG-30 and 50-AAGGTGG
TGCAAGTGGACAGA-30 ; actin, 50-CGCGAGAAGATGACCCAGAT-30 and
50-ACAGCCTGGATAGCAACGTACAT-30 . The expression of each gene was
defined from the threshold cycle (Ct), and the relative expression levels were
calculated using the 2-DDCt method after normalization to the actin expression
level.
Lentiviral vector constructs and infection. miR-1269a was ectopically expressed
by the GFP hsa-miR-1269a Letivector and silenced by the inhibitor hsa-miR-1269a
Letivector. These two vectors and the control vectors were ordered from Applied
Biological Material. The Smad7 luciferase reporter, with the Smad7 30UTR in the
pMirtarget Vector, was ordered from OriGene. The HOXD10 luciferase reporter,
pMIR-D10 UTR, was order from Addgene. miR-1269a-binding sequences in the
Smad7 and HOXD10 luciferase reporters were mutated using the QuickChange
Site-directed Mutagenesis Kit (Stratagene). To construct the reporter for miR-
1269a promoter activity, the miR-1269a promoter sequence was amplified from
human genomic DNA and cloned into the pGL4.10 vector (Promega). The putative
Sox4-binding site in the miR-1269a promoter sequence was further mutated using
the QuickChange Site-directed Mutagenesis Kit (Stratagene). Expression vectors
for HOXD10, Smad7, Sox4, Slug and Snail (HOXD10-pcDNA, pBabe-puro-
Smad7-HA, pWPXL-Sox4, pBabe-puro-Slug and pBabe-puro-Snail) were ordered
from the Addgene. Short hairpin RNA constructs against HOXD10 and Smad7
were ordered from the Sigma. The reporter construct carrying luciferase and
mCherry was order from the Addgene. The lentiviral vectors were co-transfected
with helper plasmids into 293T cells. The retroviral vectors were transfected into
phoenix cells. The viral supernatant was collected 48 h after transfection and was
used to infect CRC cells.
Luciferase reporter assay. To validate the Sox4-binding sites in the miR-1269a
promoter, miR-1269a promoter reporter construct with wide-type or mutated
Sox4-binding sites was transfected with the pRL-SV40 Renilla luciferase vectors
into SW480 and HT29 cells using the LT1 Transfection Reagent (Mirus). To
validate whether HOXD10 and Smad7 are direct targets of miR-1269a, HOXD10
and Smad7 luciferase reporter constructs with wide-type or mutated miR-1269a-
binding sites were transfected with the pRL-SV40 Renilla luciferase vector into
SW480 and HT29 cells. 48 h after transfection, Luciferase assays were performed
using the dual luciferase reporter assay system (Promega). Measurements from
triplicate transfections were analysed after normalization to the Firefly luciferase
activity.
Immunofluorescence. Cells were grown on glass culture slides (BD Biosciences)
and fixed with 4% cold methanol at  20 C for 10 min. Subsequently, cells were
blocked with 10% goat serum for 1 h and incubated with primary antibodies
against E-cadherin (24E10, 1:200, Cell Signaling), N-cadherin (1:100, BD Bios-
ciences) and Vimentin (D21H3, 1:100, Cell Signaling) at 4 C for 1 h and then
incubated with Rhodamine Red or Alexa Fluor 488-labelled secondary antibody
(Invitrogen) for 1 h at room temperature. After counterstained with DAPI (Invi-
trogen), the slide was observed under a confocal microscope (Zeiss).
Chromatin immunoprecipitation assay. ChIP was performed using a ChIP assay
kit (Millipore) according to the manufacturer’s instructions. Briefly, SW480 and
HT29 cells either infected with a vector-expressing Sox4 or treated with TGF-b1
were incubated in 1% formaldehyde for 10 min at room temperature to crosslink
their DNA. The cells were lysed in lysis buffer, sonicated to generate DNA
fragments less than 500 base pairs in length and then diluted by tenfolds in ChIP
Dilution Buffer. Before immunoprecipitation, nuclear extracts were pre-cleared
with 50% protein G–Sepharose slurry, goat normal serum and sheared salmon
sperm DNA for 2 h at 4 C. Anti-Sox4 antibody (H-90, 1:50, Santa Cruz) was then
added to form complexes with Sox4 protein and associated chromatin. These
immunocomplexes were recovered by protein G–Sepharose beads, and the
associated DNA was purified by extraction with phenol/chloroform. PCR Primers
50-CAGTGGATTGAGTGAGGAAGATTCT-30 and 50-TGAGCCCCAGAGTC
CAAGAG-30 for site 1 and primers 50-CCCTCACAGCAATTTTATAGCATCT-30
and 50-TCAAACAAATATGCCAGTCACTTCA-30 were used to measure the
enrichment of the putative Sox4-binding site in the miR-1269a promoter.
Western blot. Whole-cell lysate was prepared in a lysis buffer (20 mM Tris (pH
7.5), 150 mM NaCl, 1% Nonidet P-40, 0.5% Sodium Deoxycholate, 1 mM EDTA,
0.1% SDS, protease inhibitors). Proteins were first separated by 10% SDS–PAGE
and then transferred to a Hybond membrane (Amersham). The membranes were
incubated with primary antibodies either anti-E-cadherin (24E10, 1:1000, Cell
Signailing), anti-N-cadherin (1:1000, BD Biosciences), anti-HOXD10 (H-80,
1:1000, Santa Cruz), anti-Smad7 (B-8, 1:500, Santa Cruz), anti-Snail (C15D3,
1:1000, Cell Signaling), anti-Slug (C19G7, 1:1000, Cell Signaling), anti-Sox4 (C20,
1:100, Santa Cruz), anti-Phospho-Smad2 (1:1000, Cell Signaling) or anti-b-actin
(13E5, 1:1000, Cell Signaling) in 5% milk/TBST buffer (25 mM Tris pH 7.4,
150 mM NaCl, 2.5 mM KCl, 0.1% Triton-X100) overnight, and then probed for 1 h
with secondary horseradish peroxidase-conjugated anti-mouse or anti-rabbit IgG
(Santa Cruz). After extensive wash with PBST, the target proteins were detected on
membrane by enhanced chemiluminescence (Pierce). Full scans of western blots
are included in Supplementary Figs11 and 12.
Analysis of Proliferation, migration and invasion. SW480 cells were infected
with either the control or miR-1269a expression lentiviral vectors. The infection
efficiency was measured by GFP expression from the vectors. Cell proliferation
under differentiating condition was analysed using the WST-1 Cell Proliferation
Reagent (Clontech). Migration assay and invasion assay were performed as pre-
viously described. Briefly, 1 105 cells were plated in the serum-free medium in the
upper chamber with the non-coated membrane (24-well insert; pore size, 8 mm;
BD Biosciences) for migration assay and with Matrigel-coated membrane (24-well
insert; pore size, 8 mm; BD Biosciences) for invasion assay. The lower chamber was
filled with medium containing 20% fetal bovine serum. The cells were incubated for
24 h at 37 C. The cells did not traversed the membrane were removed by a cotton
swab and the cells on the lower surface of the membrane were stained with crystal
violet and observed under a microscope.
In vivo experiments. All animal experiments were approved by the Cornell Center
for Animal Resources and Education and followed the protocol (2009-0071 and
2010-0100).
For subcutaneous injection, 8 106 cancer cells were injected into the lower
back region of 5-week-old female nude mice, with five mice per group. The mice
were killed and the tumours were collected and weighed when one of the mice had
developed severe tumour burden.
For intravenous injection, 2 106 cancer cells were injected into 5-week-old
female NOD/SCID mice, with ten mice per group. The mice were killed and lung/
liver metastasis was evaluated when one of them became moribund.
For cecum injection, cells were carrying a reporter construct expressing
luciferase and mCherry. After FACS sorting, 4 106 cells were injected into
5-week-old female NOD/SCID mice, with eight mice per group. After injection,
luciferase signal was tracked in vivo using the IVIS luciferase imaging system 200
(Xenogen). When one of the mice became moribund, all mice were killed and
liver metastases were evaluated based on mCherry signals by an OV100 microscope
(Olympus).
Immunohistochemistry. Lung and liver tissues from mice injected with CRC cells
with miR-1269a expression or silencing vectors were removed and fixed in 4%
paraformaldehyde overnight. Paraffin-embedded sections were processed for H&E
staining.
Bioinformatics analysis. microRNA expression profiles of CRC tumours at dif-
ferent stages were compared by analysing miRNASeq data from the TCGA COAD
data set. A total of 409 samples were grouped according to the AJCC tumour-node-
metastasis staging. Stage I (68 samples) and Stage II (162 samples) CRCs were
combined to form the early-stage CRC cohort, which was compared with stage IV
samples (59 samples) as the late-stage cohort. DESeq was used for differential
analysis of the microRNA expression profiling between early- (stage I and II) and
late-stage (stage IV) CRC cohorts.
Statistical analysis. Data were expressed as mean±standard deviation of no
smaller than three biological repeats, unless otherwise noted. Student’s t-tests were
used for comparisons, with Po0.05 considered significant. Survival curves were
estimated using the Kaplan–Meier method and compared using the logrank test.
The multivariate analysis was performed with a Cox’s proportional hazards model.
Hazard ratios and 95% confidence intervals were derived from the model and the
likelihood ratio test was used to compare the groups.
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